nodes	percent_of_prediction	percent_of_DWPC	metapath
Sucralfate—EGF—lung cancer	0.59	0.924	CbGaD
Sucralfate—ALB—lung cancer	0.0484	0.0758	CbGaD
Sucralfate—ALB—Gefitinib—lung cancer	0.031	0.415	CbGbCtD
Sucralfate—ALB—Erlotinib—lung cancer	0.0183	0.246	CbGbCtD
Sucralfate—ALB—Irinotecan—lung cancer	0.0165	0.222	CbGbCtD
Sucralfate—ALB—Methotrexate—lung cancer	0.00876	0.117	CbGbCtD
Sucralfate—FGB—mammary gland—lung cancer	0.007	0.127	CbGeAlD
Sucralfate—FGB—respiratory system—lung cancer	0.00467	0.0844	CbGeAlD
Sucralfate—EGF—mammary gland—lung cancer	0.00438	0.0791	CbGeAlD
Sucralfate—FGF2—mammary gland—lung cancer	0.00386	0.0698	CbGeAlD
Sucralfate—FGG—lung—lung cancer	0.00321	0.058	CbGeAlD
Sucralfate—EGF—respiratory system—lung cancer	0.00292	0.0527	CbGeAlD
Sucralfate—FGB—bone marrow—lung cancer	0.00273	0.0494	CbGeAlD
Sucralfate—Haemolysis—Cisplatin—lung cancer	0.00268	0.049	CcSEcCtD
Sucralfate—FGA—Podofilox—Teniposide—lung cancer	0.00259	0.627	CbGdCrCtD
Sucralfate—FGB—lung—lung cancer	0.00248	0.0448	CbGeAlD
Sucralfate—EGF—epithelium—lung cancer	0.00244	0.0441	CbGeAlD
Sucralfate—FGA—bone marrow—lung cancer	0.00234	0.0423	CbGeAlD
Sucralfate—FGG—lymph node—lung cancer	0.00219	0.0397	CbGeAlD
Sucralfate—EGF—trachea—lung cancer	0.00216	0.039	CbGeAlD
Sucralfate—FGA—lung—lung cancer	0.00212	0.0383	CbGeAlD
Sucralfate—FGF2—bronchus—lung cancer	0.00212	0.0383	CbGeAlD
Sucralfate—Extravasation—Teniposide—lung cancer	0.00206	0.0376	CcSEcCtD
Sucralfate—EGF—cardiac atrium—lung cancer	0.00202	0.0366	CbGeAlD
Sucralfate—FGF2—trachea—lung cancer	0.0019	0.0344	CbGeAlD
Sucralfate—Lung disorder—Topotecan—lung cancer	0.00188	0.0343	CcSEcCtD
Sucralfate—Lung disorder—Erlotinib—lung cancer	0.00186	0.034	CcSEcCtD
Sucralfate—Lung disorder—Vinorelbine—lung cancer	0.00161	0.0294	CcSEcCtD
Sucralfate—Venous thrombosis—Cisplatin—lung cancer	0.00158	0.0288	CcSEcCtD
Sucralfate—Extravasation—Vinblastine—lung cancer	0.00157	0.0287	CcSEcCtD
Sucralfate—EGF—lung—lung cancer	0.00155	0.028	CbGeAlD
Sucralfate—FGA—Podofilox—Etoposide—lung cancer	0.00154	0.373	CbGdCrCtD
Sucralfate—Extravasation—Topotecan—lung cancer	0.00152	0.0279	CcSEcCtD
Sucralfate—ALB—mammary gland—lung cancer	0.00151	0.0273	CbGeAlD
Sucralfate—Phlebitis—Teniposide—lung cancer	0.00151	0.0276	CcSEcCtD
Sucralfate—Venous thrombosis—Paclitaxel—lung cancer	0.00142	0.0259	CcSEcCtD
Sucralfate—Fluid overload—Cisplatin—lung cancer	0.00137	0.025	CcSEcCtD
Sucralfate—FGF2—lung—lung cancer	0.00137	0.0247	CbGeAlD
Sucralfate—Lung disorder—Irinotecan—lung cancer	0.00133	0.0242	CcSEcCtD
Sucralfate—Extravasation—Vinorelbine—lung cancer	0.0013	0.0238	CcSEcCtD
Sucralfate—Phlebitis—Vinblastine—lung cancer	0.00115	0.0211	CcSEcCtD
Sucralfate—Extravasation—Irinotecan—lung cancer	0.00108	0.0197	CcSEcCtD
Sucralfate—EGF—lymph node—lung cancer	0.00106	0.0191	CbGeAlD
Sucralfate—Extravasation—Gemcitabine—lung cancer	0.00105	0.0191	CcSEcCtD
Sucralfate—Extravasation—Cisplatin—lung cancer	0.000976	0.0178	CcSEcCtD
Sucralfate—Phlebitis—Vinorelbine—lung cancer	0.000959	0.0175	CcSEcCtD
Sucralfate—FGF2—lymph node—lung cancer	0.000934	0.0169	CbGeAlD
Sucralfate—Extravasation—Etoposide—lung cancer	0.000894	0.0163	CcSEcCtD
Sucralfate—Extravasation—Paclitaxel—lung cancer	0.000877	0.016	CcSEcCtD
Sucralfate—Oedema—Crizotinib—lung cancer	0.000865	0.0158	CcSEcCtD
Sucralfate—Infection—Crizotinib—lung cancer	0.000859	0.0157	CcSEcCtD
Sucralfate—Hyponatraemia—Vinorelbine—lung cancer	0.000829	0.0152	CcSEcCtD
Sucralfate—Oedema—Pemetrexed—lung cancer	0.00079	0.0144	CcSEcCtD
Sucralfate—Infection—Pemetrexed—lung cancer	0.000785	0.0144	CcSEcCtD
Sucralfate—Infection—Gefitinib—lung cancer	0.00078	0.0143	CcSEcCtD
Sucralfate—Venous thrombosis—Doxorubicin—lung cancer	0.00075	0.0137	CcSEcCtD
Sucralfate—Extravasation—Docetaxel—lung cancer	0.000743	0.0136	CcSEcCtD
Sucralfate—Phlebitis—Cisplatin—lung cancer	0.000718	0.0131	CcSEcCtD
Sucralfate—Hyponatraemia—Irinotecan—lung cancer	0.000684	0.0125	CcSEcCtD
Sucralfate—Body temperature increased—Crizotinib—lung cancer	0.000684	0.0125	CcSEcCtD
Sucralfate—Lung disorder—Methotrexate—lung cancer	0.00066	0.0121	CcSEcCtD
Sucralfate—Phlebitis—Etoposide—lung cancer	0.000658	0.012	CcSEcCtD
Sucralfate—Phlebitis—Paclitaxel—lung cancer	0.000645	0.0118	CcSEcCtD
Sucralfate—Oedema—Teniposide—lung cancer	0.00064	0.0117	CcSEcCtD
Sucralfate—Infection—Teniposide—lung cancer	0.000636	0.0116	CcSEcCtD
Sucralfate—Body temperature increased—Pemetrexed—lung cancer	0.000625	0.0114	CcSEcCtD
Sucralfate—Hyponatraemia—Cisplatin—lung cancer	0.000621	0.0113	CcSEcCtD
Sucralfate—Body temperature increased—Gefitinib—lung cancer	0.000621	0.0113	CcSEcCtD
Sucralfate—Lung disorder—Doxorubicin—lung cancer	0.000572	0.0105	CcSEcCtD
Sucralfate—Hyponatraemia—Paclitaxel—lung cancer	0.000558	0.0102	CcSEcCtD
Sucralfate—Phlebitis—Docetaxel—lung cancer	0.000546	0.00999	CcSEcCtD
Sucralfate—Extravasation—Methotrexate—lung cancer	0.000536	0.00979	CcSEcCtD
Sucralfate—Body temperature increased—Teniposide—lung cancer	0.000506	0.00925	CcSEcCtD
Sucralfate—Hyponatraemia—Docetaxel—lung cancer	0.000473	0.00864	CcSEcCtD
Sucralfate—Infection—Topotecan—lung cancer	0.000471	0.00862	CcSEcCtD
Sucralfate—Oedema—Erlotinib—lung cancer	0.000469	0.00858	CcSEcCtD
Sucralfate—Infection—Erlotinib—lung cancer	0.000466	0.00852	CcSEcCtD
Sucralfate—Extravasation—Doxorubicin—lung cancer	0.000464	0.00848	CcSEcCtD
Sucralfate—Infection—Vinorelbine—lung cancer	0.000403	0.00737	CcSEcCtD
Sucralfate—Body temperature increased—Topotecan—lung cancer	0.000375	0.00686	CcSEcCtD
Sucralfate—Body temperature increased—Erlotinib—lung cancer	0.000371	0.00678	CcSEcCtD
Sucralfate—ALB—lymph node—lung cancer	0.000366	0.00662	CbGeAlD
Sucralfate—Phlebitis—Doxorubicin—lung cancer	0.000341	0.00623	CcSEcCtD
Sucralfate—Oedema—Irinotecan—lung cancer	0.000335	0.00612	CcSEcCtD
Sucralfate—Infection—Irinotecan—lung cancer	0.000333	0.00608	CcSEcCtD
Sucralfate—Oedema—Gemcitabine—lung cancer	0.000326	0.00596	CcSEcCtD
Sucralfate—Infection—Gemcitabine—lung cancer	0.000324	0.00592	CcSEcCtD
Sucralfate—Body temperature increased—Vinorelbine—lung cancer	0.000321	0.00586	CcSEcCtD
Sucralfate—Oedema—Cisplatin—lung cancer	0.000304	0.00555	CcSEcCtD
Sucralfate—Infection—Cisplatin—lung cancer	0.000302	0.00552	CcSEcCtD
Sucralfate—Hyponatraemia—Doxorubicin—lung cancer	0.000295	0.00539	CcSEcCtD
Sucralfate—Infection—Etoposide—lung cancer	0.000277	0.00506	CcSEcCtD
Sucralfate—Oedema—Paclitaxel—lung cancer	0.000273	0.00499	CcSEcCtD
Sucralfate—Infection—Paclitaxel—lung cancer	0.000271	0.00496	CcSEcCtD
Sucralfate—Body temperature increased—Irinotecan—lung cancer	0.000265	0.00484	CcSEcCtD
Sucralfate—Body temperature increased—Gemcitabine—lung cancer	0.000258	0.00471	CcSEcCtD
Sucralfate—Body temperature increased—Cisplatin—lung cancer	0.00024	0.00439	CcSEcCtD
Sucralfate—Oedema—Docetaxel—lung cancer	0.000231	0.00423	CcSEcCtD
Sucralfate—Infection—Docetaxel—lung cancer	0.00023	0.0042	CcSEcCtD
Sucralfate—Body temperature increased—Etoposide—lung cancer	0.00022	0.00402	CcSEcCtD
Sucralfate—Body temperature increased—Paclitaxel—lung cancer	0.000216	0.00394	CcSEcCtD
Sucralfate—Body temperature increased—Docetaxel—lung cancer	0.000183	0.00334	CcSEcCtD
Sucralfate—Infection—Methotrexate—lung cancer	0.000166	0.00303	CcSEcCtD
Sucralfate—Oedema—Doxorubicin—lung cancer	0.000144	0.00264	CcSEcCtD
Sucralfate—Infection—Doxorubicin—lung cancer	0.000143	0.00262	CcSEcCtD
Sucralfate—Body temperature increased—Methotrexate—lung cancer	0.000132	0.00241	CcSEcCtD
Sucralfate—Body temperature increased—Doxorubicin—lung cancer	0.000114	0.00209	CcSEcCtD
Sucralfate—FGF2—Signaling Pathways—IGF1R—lung cancer	6e-06	3.46e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—EGFR—lung cancer	5.97e-06	3.45e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MAP2K1—lung cancer	5.96e-06	3.44e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—EGFR—lung cancer	5.93e-06	3.42e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—EGFR—lung cancer	5.93e-06	3.42e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PIK3CD—lung cancer	5.92e-06	3.42e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—HES1—lung cancer	5.9e-06	3.4e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—KRAS—lung cancer	5.88e-06	3.39e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—BRAF—lung cancer	5.84e-06	3.37e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—STAT3—lung cancer	5.82e-06	3.36e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—AVP—lung cancer	5.8e-06	3.35e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—NRAS—lung cancer	5.8e-06	3.35e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—IL6R—lung cancer	5.77e-06	3.33e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CREBBP—lung cancer	5.76e-06	3.33e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—EGFR—lung cancer	5.73e-06	3.31e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—B4GALT5—lung cancer	5.72e-06	3.3e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—KRAS—lung cancer	5.72e-06	3.3e-05	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—HRAS—lung cancer	5.66e-06	3.27e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—KRAS—lung cancer	5.64e-06	3.26e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—ABCB1—lung cancer	5.62e-06	3.25e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—KRAS—lung cancer	5.6e-06	3.23e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—KRAS—lung cancer	5.6e-06	3.23e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—SRC—lung cancer	5.58e-06	3.22e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTA4—lung cancer	5.57e-06	3.21e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—MAPK3—lung cancer	5.56e-06	3.21e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MAP2K1—lung cancer	5.5e-06	3.18e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3CD—lung cancer	5.46e-06	3.15e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	5.44e-06	3.14e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—VEGFA—lung cancer	5.43e-06	3.14e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTA2—lung cancer	5.43e-06	3.13e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MDM2—lung cancer	5.42e-06	3.13e-05	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—IL6—lung cancer	5.41e-06	3.13e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—KRAS—lung cancer	5.41e-06	3.12e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—MYC—lung cancer	5.4e-06	3.12e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—PIK3CA—lung cancer	5.4e-06	3.12e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—RAF1—lung cancer	5.4e-06	3.12e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—ERBB3—lung cancer	5.39e-06	3.11e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—MMP1—lung cancer	5.36e-06	3.09e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—ERBB2—lung cancer	5.34e-06	3.08e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MDM2—lung cancer	5.3e-06	3.06e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—EGFR—lung cancer	5.29e-06	3.05e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—RAF1—lung cancer	5.28e-06	3.05e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PIK3CB—lung cancer	5.27e-06	3.04e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MTOR—lung cancer	5.27e-06	3.04e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—PIK3CA—lung cancer	5.25e-06	3.03e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTA1—lung cancer	5.23e-06	3.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—ERBB2—lung cancer	5.23e-06	3.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—PIK3CA—lung cancer	5.18e-06	2.99e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ABCC3—lung cancer	5.18e-06	2.99e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TERT—lung cancer	5.17e-06	2.98e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MTOR—lung cancer	5.16e-06	2.98e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PIK3CB—lung cancer	5.16e-06	2.98e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CD4—lung cancer	5.15e-06	2.97e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—PIK3CA—lung cancer	5.15e-06	2.97e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—PIK3CA—lung cancer	5.15e-06	2.97e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—MAPK3—lung cancer	5.14e-06	2.97e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—APOA1—lung cancer	5.13e-06	2.96e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—TP53—lung cancer	5.08e-06	2.93e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CXCL8—lung cancer	5.06e-06	2.92e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FGFR1—lung cancer	5.02e-06	2.9e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—AKR1C1—lung cancer	5.01e-06	2.89e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—HRAS—lung cancer	5e-06	2.88e-05	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—AKT1—lung cancer	4.99e-06	2.88e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—KRAS—lung cancer	4.99e-06	2.88e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—TP53—lung cancer	4.98e-06	2.88e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—TP53—lung cancer	4.98e-06	2.88e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—PIK3CA—lung cancer	4.97e-06	2.87e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—HIF1A—lung cancer	4.94e-06	2.85e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MDM2—lung cancer	4.9e-06	2.83e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—RAF1—lung cancer	4.88e-06	2.82e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—UGT1A1—lung cancer	4.87e-06	2.81e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—HRAS—lung cancer	4.86e-06	2.81e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CASP3—lung cancer	4.85e-06	2.8e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—IL2—lung cancer	4.84e-06	2.79e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—ERBB2—lung cancer	4.83e-06	2.79e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—HRAS—lung cancer	4.8e-06	2.77e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—IL6—lung cancer	4.78e-06	2.76e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—APOA1—lung cancer	4.77e-06	2.75e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MTOR—lung cancer	4.76e-06	2.75e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3CB—lung cancer	4.76e-06	2.75e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—HRAS—lung cancer	4.76e-06	2.75e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—HRAS—lung cancer	4.76e-06	2.75e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CD4—lung cancer	4.75e-06	2.74e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL2—lung cancer	4.74e-06	2.74e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KDR—lung cancer	4.73e-06	2.73e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PTGS2—lung cancer	4.72e-06	2.72e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CCND1—lung cancer	4.72e-06	2.72e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—JUN—lung cancer	4.71e-06	2.72e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GNG11—lung cancer	4.69e-06	2.71e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CG—lung cancer	4.68e-06	2.7e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—APOA1—lung cancer	4.67e-06	2.7e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—IL6—lung cancer	4.65e-06	2.69e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—EGF—lung cancer	4.63e-06	2.67e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—JUN—lung cancer	4.61e-06	2.66e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—HRAS—lung cancer	4.6e-06	2.65e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—PIK3CA—lung cancer	4.59e-06	2.65e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MMP9—lung cancer	4.58e-06	2.64e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CDKN1A—lung cancer	4.56e-06	2.64e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—IL6—lung cancer	4.56e-06	2.63e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—IL6—lung cancer	4.56e-06	2.63e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PTEN—lung cancer	4.55e-06	2.63e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CDKN1A—lung cancer	4.47e-06	2.58e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ALDOA—lung cancer	4.47e-06	2.58e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PTEN—lung cancer	4.46e-06	2.57e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—APOA1—lung cancer	4.44e-06	2.56e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—AKT1—lung cancer	4.41e-06	2.55e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—IL6—lung cancer	4.4e-06	2.54e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—APC—lung cancer	4.35e-06	2.51e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CG—lung cancer	4.35e-06	2.51e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KIT—lung cancer	4.35e-06	2.51e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—EP300—lung cancer	4.34e-06	2.51e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—CREBBP—lung cancer	4.34e-06	2.51e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NCOA3—lung cancer	4.34e-06	2.5e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EGF—lung cancer	4.3e-06	2.48e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—AKT1—lung cancer	4.29e-06	2.48e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	4.26e-06	2.46e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—EP300—lung cancer	4.25e-06	2.45e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—HRAS—lung cancer	4.24e-06	2.45e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—PIK3CA—lung cancer	4.24e-06	2.45e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—AKT1—lung cancer	4.24e-06	2.45e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—SRC—lung cancer	4.22e-06	2.44e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ADCY1—lung cancer	4.22e-06	2.44e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ABCG2—lung cancer	4.22e-06	2.44e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—AKT1—lung cancer	4.21e-06	2.43e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—AKT1—lung cancer	4.21e-06	2.43e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—POMC—lung cancer	4.14e-06	2.39e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HPGDS—lung cancer	4.14e-06	2.39e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ENO2—lung cancer	4.14e-06	2.39e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—SRC—lung cancer	4.13e-06	2.39e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CDKN1A—lung cancer	4.13e-06	2.38e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PTEN—lung cancer	4.12e-06	2.38e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CD—lung cancer	4.12e-06	2.38e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—VEGFA—lung cancer	4.11e-06	2.37e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PPP2R1B—lung cancer	4.11e-06	2.37e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—BRAF—lung cancer	4.09e-06	2.36e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—STAT3—lung cancer	4.07e-06	2.35e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—NRAS—lung cancer	4.06e-06	2.35e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—IL6—lung cancer	4.06e-06	2.35e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—AKT1—lung cancer	4.06e-06	2.34e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—POMC—lung cancer	4.06e-06	2.34e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL6R—lung cancer	4.04e-06	2.33e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CREBBP—lung cancer	4.04e-06	2.33e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTT1—lung cancer	4.01e-06	2.32e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—STAT3—lung cancer	3.99e-06	2.3e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—NRAS—lung cancer	3.98e-06	2.3e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP2A6—lung cancer	3.97e-06	2.29e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GCLC—lung cancer	3.97e-06	2.29e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.95e-06	2.28e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—EP300—lung cancer	3.93e-06	2.27e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MAPK3—lung cancer	3.89e-06	2.25e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MAP2K1—lung cancer	3.85e-06	2.22e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CD—lung cancer	3.83e-06	2.21e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—SRC—lung cancer	3.82e-06	2.2e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MAPK3—lung cancer	3.81e-06	2.2e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MYC—lung cancer	3.78e-06	2.18e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ENO1—lung cancer	3.76e-06	2.17e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—CREBBP—lung cancer	3.76e-06	2.17e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—AKT1—lung cancer	3.75e-06	2.16e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	3.75e-06	2.16e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—EGFR—lung cancer	3.7e-06	2.14e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—STAT3—lung cancer	3.68e-06	2.13e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—RAF1—lung cancer	3.67e-06	2.12e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—NRAS—lung cancer	3.67e-06	2.12e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—EGFR—lung cancer	3.62e-06	2.09e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CB—lung cancer	3.59e-06	2.07e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MAPK3—lung cancer	3.52e-06	2.03e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—KRAS—lung cancer	3.5e-06	2.02e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—AKT1—lung cancer	3.47e-06	2e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MDM2—lung cancer	3.43e-06	1.98e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—KRAS—lung cancer	3.42e-06	1.98e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MYC—lung cancer	3.42e-06	1.97e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—RAF1—lung cancer	3.42e-06	1.97e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—ERBB2—lung cancer	3.38e-06	1.95e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP2E1—lung cancer	3.37e-06	1.95e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—EGFR—lung cancer	3.35e-06	1.93e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MTOR—lung cancer	3.34e-06	1.93e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CB—lung cancer	3.34e-06	1.93e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NQO1—lung cancer	3.34e-06	1.93e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—IL2—lung cancer	3.29e-06	1.9e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.27e-06	1.89e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.24e-06	1.87e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PIK3CA—lung cancer	3.21e-06	1.85e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CXCL8—lung cancer	3.21e-06	1.85e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—RAF1—lung cancer	3.18e-06	1.84e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—KRAS—lung cancer	3.16e-06	1.82e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PIK3CA—lung cancer	3.14e-06	1.82e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—TP53—lung cancer	3.11e-06	1.79e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CASP3—lung cancer	3.07e-06	1.77e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL2—lung cancer	3.06e-06	1.77e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—STK11—lung cancer	3.01e-06	1.74e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CCND1—lung cancer	2.99e-06	1.72e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—JUN—lung cancer	2.98e-06	1.72e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—HRAS—lung cancer	2.97e-06	1.72e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—EP300—lung cancer	2.96e-06	1.71e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—HRAS—lung cancer	2.91e-06	1.68e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3CA—lung cancer	2.9e-06	1.68e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MMP9—lung cancer	2.9e-06	1.67e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CDKN1A—lung cancer	2.89e-06	1.67e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PTEN—lung cancer	2.88e-06	1.66e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—SRC—lung cancer	2.87e-06	1.66e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—IL6—lung cancer	2.84e-06	1.64e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.82e-06	1.63e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—VEGFA—lung cancer	2.8e-06	1.62e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL6—lung cancer	2.78e-06	1.61e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTP1—lung cancer	2.78e-06	1.61e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—NRAS—lung cancer	2.77e-06	1.6e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EP300—lung cancer	2.75e-06	1.59e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CAT—lung cancer	2.71e-06	1.56e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.69e-06	1.55e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—HRAS—lung cancer	2.69e-06	1.55e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—SRC—lung cancer	2.67e-06	1.54e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—MAPK3—lung cancer	2.65e-06	1.53e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ABCB1—lung cancer	2.63e-06	1.52e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—AKT1—lung cancer	2.62e-06	1.52e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—VEGFA—lung cancer	2.6e-06	1.5e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—TYMS—lung cancer	2.59e-06	1.49e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—STAT3—lung cancer	2.58e-06	1.49e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NRAS—lung cancer	2.57e-06	1.48e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—IL6—lung cancer	2.57e-06	1.48e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—AKT1—lung cancer	2.57e-06	1.48e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTM1—lung cancer	2.56e-06	1.48e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MAPK3—lung cancer	2.46e-06	1.42e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP1A1—lung cancer	2.42e-06	1.4e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ERCC2—lung cancer	2.4e-06	1.39e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MYC—lung cancer	2.4e-06	1.38e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—KRAS—lung cancer	2.38e-06	1.37e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—AKT1—lung cancer	2.37e-06	1.37e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EGFR—lung cancer	2.34e-06	1.35e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KRAS—lung cancer	2.21e-06	1.28e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CA—lung cancer	2.19e-06	1.26e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—TP53—lung cancer	2.12e-06	1.22e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—APOA1—lung cancer	2.08e-06	1.2e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CA—lung cancer	2.03e-06	1.17e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—HRAS—lung cancer	2.02e-06	1.17e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.99e-06	1.15e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TP53—lung cancer	1.97e-06	1.14e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CG—lung cancer	1.9e-06	1.1e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—HRAS—lung cancer	1.88e-06	1.09e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—POMC—lung cancer	1.81e-06	1.04e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL6—lung cancer	1.8e-06	1.04e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—AKT1—lung cancer	1.79e-06	1.03e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CREBBP—lung cancer	1.76e-06	1.02e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CD—lung cancer	1.67e-06	9.63e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—AKT1—lung cancer	1.66e-06	9.59e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CB—lung cancer	1.45e-06	8.4e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTGS2—lung cancer	1.44e-06	8.32e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTEN—lung cancer	1.26e-06	7.26e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—EP300—lung cancer	1.2e-06	6.92e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CA—lung cancer	8.87e-07	5.12e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—AKT1—lung cancer	7.24e-07	4.18e-06	CbGpPWpGaD
